<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Res Ther</journal-id><journal-id journal-id-type="iso-abbrev">Arthritis Res. Ther</journal-id><journal-title-group><journal-title>Arthritis Research &#x00026; Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-6354</issn><issn pub-type="epub">1478-6362</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25011482</article-id><article-id pub-id-type="pmc">4227041</article-id><article-id pub-id-type="publisher-id">ar4608</article-id><article-id pub-id-type="doi">10.1186/ar4608</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title><italic>Interferon regulatory factor 5</italic> genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="A1"><name><surname>Garc&#x000ed;a-Berm&#x000fa;dez</surname><given-names>Mercedes</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>mgbermudez@ipb.csic.es</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A2"><name><surname>L&#x000f3;pez-Mej&#x000ed;as</surname><given-names>Raquel</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>rlopezmejias78@gmail.com</email></contrib><contrib contrib-type="author" equal-contrib="yes" id="A3"><name><surname>Genre</surname><given-names>Fernanda</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>fernandagenre@gmail.com</email></contrib><contrib contrib-type="author" id="A4"><name><surname>Casta&#x000f1;eda</surname><given-names>Santos</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>scastas@gmail.com</email></contrib><contrib contrib-type="author" id="A5"><name><surname>Llorca</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>llorcaj@unican.es</email></contrib><contrib contrib-type="author" id="A6"><name><surname>Gonz&#x000e1;lez-Juanatey</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>carlosjuanatey@secardiologia.es</email></contrib><contrib contrib-type="author" id="A7"><name><surname>Corrales</surname><given-names>Alfonso</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>afcorralesm@hotmail.com</email></contrib><contrib contrib-type="author" id="A8"><name><surname>Ubilla</surname><given-names>Bego&#x000f1;a</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>b.ubilla.garcia@gmail.com</email></contrib><contrib contrib-type="author" id="A9"><name><surname>Miranda-Filloy</surname><given-names>Jos&#x000e9; A</given-names></name><xref ref-type="aff" rid="I6">6</xref><email>jose.alberto.miranda.filloy@sergas.es</email></contrib><contrib contrib-type="author" id="A10"><name><surname>Pina</surname><given-names>Trinitario</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>alicantrino@hotmail.com</email></contrib><contrib contrib-type="author" id="A11"><name><surname>G&#x000f3;mez-Vaquero</surname><given-names>Carmen</given-names></name><xref ref-type="aff" rid="I7">7</xref><email>carmen.gomez@bellvitgehospital.cat</email></contrib><contrib contrib-type="author" id="A12"><name><surname>Rodr&#x000ed;guez-Rodr&#x000ed;guez</surname><given-names>Luis</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>lrodriguezr.hcsc@salud.madrid.org</email></contrib><contrib contrib-type="author" id="A13"><name><surname>Fern&#x000e1;ndez-Guti&#x000e9;rrez</surname><given-names>Benjam&#x000ed;n</given-names></name><xref ref-type="aff" rid="I8">8</xref><email>bfernandez.hcsc@salud.madrid.org</email></contrib><contrib contrib-type="author" id="A14"><name><surname>Balsa</surname><given-names>Alejandro</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>al.balsa@telefonica.net</email></contrib><contrib contrib-type="author" id="A15"><name><surname>Pascual-Salcedo</surname><given-names>Dora</given-names></name><xref ref-type="aff" rid="I9">9</xref><email>dpascual.hulp@salud.madrid.org</email></contrib><contrib contrib-type="author" id="A16"><name><surname>L&#x000f3;pez-Longo</surname><given-names>Francisco J</given-names></name><xref ref-type="aff" rid="I10">10</xref><email>fjlopezlongo@hotmail.com</email></contrib><contrib contrib-type="author" id="A17"><name><surname>Carreira</surname><given-names>Patricia</given-names></name><xref ref-type="aff" rid="I11">11</xref><email>carreira@h12o.es</email></contrib><contrib contrib-type="author" id="A18"><name><surname>Blanco</surname><given-names>Ricardo</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>rblanco@humv.es</email></contrib><contrib contrib-type="author" id="A19"><name><surname>Mart&#x000ed;n</surname><given-names>Javier</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>martin@ipb.csic.es</email></contrib><contrib contrib-type="author" corresp="yes" id="A20"><name><surname>Gonz&#x000e1;lez-Gay</surname><given-names>Miguel A</given-names></name><xref ref-type="aff" rid="I2">2</xref><xref ref-type="aff" rid="I12">12</xref><email>miguelaggay@hotmail.com</email></contrib></contrib-group><aff id="I1"><label>1</label>Institute of Parasitology and Biomedicine L&#x000f3;pez-Neyra, IPBLN-CSIC, Parque Tecnol&#x000f3;gico de Ciencias de la Salud, Avenida del Conocimiento s/n, Armilla, 18100 Granada, Spain</aff><aff id="I2"><label>2</label>Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Avenida Cardenal Herrera Oria s/n, 39011 Santander, Spain</aff><aff id="I3"><label>3</label>Department of Rheumatology, Hospital Universitario la Princesa, IIS-Princesa, Diego de Le&#x000f3;n 62, 28006 Madrid, Spain</aff><aff id="I4"><label>4</label>Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiolog&#x000ed;a y Salud P&#x000fa;blica (CIBERESP), IDIVAL, Avenida Cardenal Herrera Oria s/n, 39011 Santander, Spain</aff><aff id="I5"><label>5</label>Cardiology Division, Hospital Universitario Lucus Augusti, Doctor Ochoa s/n, 27004 Lugo, Spain</aff><aff id="I6"><label>6</label>Department of Rheumatology, Hospital Universitario Lucus Augusti, Doctor Ochoa s/n, 27004 Lugo, Spain</aff><aff id="I7"><label>7</label>Department of Rheumatology, Hospital Universitario Bellvitge, Feixa Llarga s/n, 08907 Barcelona, Spain</aff><aff id="I8"><label>8</label>Department of Rheumatology, Hospital Cl&#x000ed;nico San Carlos, Profesor Mart&#x000ed;n Lagos s/n, 28040 Madrid, Spain</aff><aff id="I9"><label>9</label>Department of Rheumatology, Hospital Universitario La Paz, Paseo de la Castellana 261, 28046 Madrid, Spain</aff><aff id="I10"><label>10</label>Department of Rheumatology, Hospital General Universitario Gregorio Mara&#x000f1;&#x000f3;n, Doctor Esquerdo 46, 28007 Madrid, Spain</aff><aff id="I11"><label>11</label>Department of Rheumatology, Hospital Universitario 12 de Octubre, Avenida de C&#x000f3;rdoba s/n, 28041 Madrid, Spain</aff><aff id="I12"><label>12</label>Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, 1 Jan Smuts Avenue Braamfontei, 2000 Johannesburg, South Africa</aff><pub-date pub-type="ppub"><year>2014</year></pub-date><pub-date pub-type="epub"><day>10</day><month>7</month><year>2014</year></pub-date><volume>16</volume><issue>4</issue><fpage>R146</fpage><lpage>R146</lpage><history><date date-type="received"><day>11</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>17</day><month>6</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 Garc&#x000ed;a-Berm&#x000fa;dez et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>Garc&#x000ed;a-Berm&#x000fa;dez et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://arthritis-research.com/content/16/4/R146"/><abstract><sec><title>Introduction</title><p>Rheumatoid arthritis (RA) is a complex polygenic inflammatory disease associated with accelerated atherosclerosis and increased cardiovascular (CV) disease risk. Interferon regulatory factor 5 (IRF5) is a regulator of type I interferon induction. Recently, researchers have described an association between multiple single-nucleotide polymorphisms of the <italic>IRF5</italic> gene and some rheumatic disorders. In this study, we aimed to evaluate whether three different haplotype blocks within the <italic>IRF5</italic> locus which have been shown to alter the protein function are involved in the risk of CV events occurring in Spanish RA patients.</p></sec><sec><title>Methods</title><p>Three <italic>IRF5</italic> polymorphisms (rs2004640, rs2070197 and rs10954213) representative of each haplotype group were genotyped by performing TaqMan assays using a 7900HT Fast Real-Time PCR System with tissue from a total of 2,137 Spanish patients diagnosed with RA. Among them, 390 (18.2%) had experienced CV events. The relationship of <italic>IRF5</italic> genotypes and haplotypes to CV events was tested using Cox regression.</p></sec><sec><title>Results</title><p>Male sex, age at RA diagnosis and most traditional risk factors (hypertension, dyslipidemia and smoking habit) were associated with increased risk for CV events in the RA population. Interestingly, a protective effect of both <italic>IRF5</italic> rs2004640 GG and <italic>IRF5</italic> rs10954213 GG genotypes against the risk for CV events after adjusting the results for sex, age at RA diagnosis and traditional CV disease risk factors was observed (hazard ratio (HR)&#x02009;=&#x02009;0.6, 95% confidence interval (CI)&#x02009;=&#x02009;0.38 to 0.92, <italic>P</italic>&#x02009;=&#x02009;0.02; and HR&#x02009;=&#x02009;0.58, 95% CI&#x02009;=&#x02009;0.36 to 0.95, <italic>P</italic>&#x02009;=&#x02009;0.03, respectively). Moreover, we detected a protective effect of the GTG haplotype against the risk for CV events after adjusting the results for potential confounding factors (HR&#x02009;=&#x02009;0.72, 95% CI&#x02009;=&#x02009;0.56 to 0.93, <italic>P</italic>&#x02009;=&#x02009;0.012).</p></sec><sec><title>Conclusions</title><p>Our results reveal that <italic>IRF5</italic> gene variants are associated with risk of CV events in patients with RA.</p></sec></abstract></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>Rheumatoid arthritis (RA) is a chronic inflammatory rheumatic disease associated with an increased risk for cardiovascular (CV) events and CV disease&#x02013;related deaths compared to the general population [<xref ref-type="bibr" rid="B1">1</xref>]. Because of that, adequate stratification of CV disease risk has special relevance in RA patients. Researchers in several studies have demonstrated that RA is an independent risk factor for premature heart disease [<xref ref-type="bibr" rid="B2">2</xref>]. This process is the result of a combined effect of traditional CV disease risk factors [<xref ref-type="bibr" rid="B3">3</xref>], the magnitude and severity of a chronic inflammatory response [<xref ref-type="bibr" rid="B4">4</xref>] and genetic factors located inside [<xref ref-type="bibr" rid="B4">4</xref>] and outside the human leukocyte antigen (HLA) region [<xref ref-type="bibr" rid="B5">5</xref>-<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Type I interferons (IFNs) are signaling molecules involved in both innate and adaptive immunity. Misregulated expression of type I <italic>IFN</italic> genes has been observed in peripheral white blood cells of patients with several autoimmune diseases [<xref ref-type="bibr" rid="B9">9</xref>]. In this regard, interferon regulatory factor 5 (IRF5) has been involved in the regulation of type I <italic>IFN</italic> gene transcription [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. This protein is critical for the production of proinflammatory cytokines [<xref ref-type="bibr" rid="B12">12</xref>], such as TNF-&#x003b1;, interleukin 12 (IL-12) and IL-6, following Toll-like receptor signaling. IRF5 also acts as a molecular switch that controls inflammatory mechanisms mediated by macrophage cells [<xref ref-type="bibr" rid="B12">12</xref>].</p><p>IRF5 protein is encoded by the <italic>IRF5</italic> gene, which is located in chromosome 7q32.1. Several genetic studies have described the relevance of multiple single-nucleotide polymorphisms (SNPs) of the <italic>IRF5</italic> gene in different rheumatic disorders, such as RA and lupus erythematosus [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. In this context, three groups of correlated <italic>IRF5</italic> variants, designated as groups 1, 2 and 3, have been found to be independently associated with these inflammatory disorders and with different functional roles. Group 1 includes SNPs tagging a 30-bp in-frame insertion/deletion variant of exon 6 that alters protein stability. The association of group 2 SNPs seems to be explained by the T allele of <italic>IRF5</italic> rs2004640 polymorphism that allows the expression of an alternative isoform and is associated with significantly higher levels of <italic>IRF5</italic> expression. The association of group 3 SNPs is probably due to the rs10954213 A allele that creates an early polyadenylation site which leads to higher <italic>IRF5</italic> expression [<xref ref-type="bibr" rid="B14">14</xref>].</p><p>Taking into account all of these considerations together in the present study, we analyzed the potential role of one tagging SNP of each group of independent signals (rs2004640, rs2070197 and rs10954213) in the risk for CV disease in a large and well-characterized cohort of patients with RA.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patients and study protocol</title><p>A set of 2,137 Spanish patients with RA were included in the present study. Blood samples were obtained from patients recruited from University Hospital Lucus Augusti (Lugo), Marqu&#x000e9;s de Valdecilla University Hospital (Santander), Hospital de Bellvitge (Barcelona) Hospital Cl&#x000ed;nico San Carlos, La Paz University Hospital, Hospital de La Princesa, University Hospital Gregorio Mara&#x000f1;&#x000f3;n and 12 de Octubre University Hospital (Madrid). Informed written consent was obtained from all participants. The study was approved by the ethics committees of Galicia for University Hospital Lucus Augusti; of Cantabria for Marqu&#x000e9;s de Valdecilla University Hospital; of Catalu&#x000f1;a for Hospital de Bellvitge; and of Madrid for Hospital Cl&#x000ed;nico San Carlos, La Paz University Hospital, Hospital de La Princesa, University Hospital Gregorio Mara&#x000f1;&#x000f3;n and 12 de Octubre University Hospital. All the patients fulfilled the RA classification criteria published by the American College of Rheumatology in 1987 and 2010 [<xref ref-type="bibr" rid="B15">15</xref>,<xref ref-type="bibr" rid="B16">16</xref>]. In all the cases, patients were assessed for the <italic>IRF5</italic> rs2004640, rs2070197 and rs10954213 polymorphisms.</p><p>Data on the main demographic data, clinical characteristics, CV disease risk factors and CV events of patients enrolled in the study are shown in Table&#x000a0;<xref ref-type="table" rid="T1">1</xref>. Three hundred ninety (18.2%) of the patients had experienced CV events. Definitions of CV events and traditional CV disease risk factors were established as previously described [<xref ref-type="bibr" rid="B4">4</xref>,<xref ref-type="bibr" rid="B17">17</xref>].</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p><bold>Demographic and clinical characteristics</bold><sup>
<bold>a</bold>
</sup></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Clinical features</bold></th><th align="left"><bold>% ( </bold><bold>
<italic>n </italic>
</bold><bold>/ </bold><bold>
<italic>N </italic>
</bold><bold>) or mean&#x02009;&#x000b1;&#x02009;SD</bold></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Patients<hr/></td><td align="left" valign="bottom">2,137<hr/></td></tr><tr><td align="left" valign="bottom">Main characteristics<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Age at disease onset (yr)<hr/></td><td align="left" valign="bottom">53&#x02009;&#x000b1;&#x02009;14.8<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Follow-up duration (yr)<hr/></td><td align="left" valign="bottom">12.5&#x02009;&#x000b1;&#x02009;8.25<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Females (%)<hr/></td><td align="left" valign="bottom">75.1<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Rheumatoid factor&#x02013;positive<sup>b</sup><hr/></td><td align="left" valign="bottom">68.3 (1,413/2,070)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Anti-CCP antibody&#x02013;positive<hr/></td><td align="left" valign="bottom">57.3 (1,024/1,785)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Shared epitope&#x02013;positive<hr/></td><td align="left" valign="bottom">62.6 (734/1,173)<hr/></td></tr><tr><td align="left" valign="bottom">Erosions<hr/></td><td align="left" valign="bottom">54.4 (866/1,591)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Extraarticular manifestations<sup>c</sup><hr/></td><td align="left" valign="bottom">31.3 (481/1,537)<hr/></td></tr><tr><td align="left" valign="bottom">Cardiovascular risk factors<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Hypertension<hr/></td><td align="left" valign="bottom">40.3 (846/2,100)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Diabetes mellitus<hr/></td><td align="left" valign="bottom">13.1 (275/2,100)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Dyslipidemia<hr/></td><td align="left" valign="bottom">38.3 (805/2,100)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Obesity<hr/></td><td align="left" valign="bottom">19.6 (413/2,100)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Smoking habit<hr/></td><td align="left" valign="bottom">27.4 (576/2,100)<hr/></td></tr><tr><td align="left" valign="bottom">Patients with cardiovascular events (total)<hr/></td><td align="left" valign="bottom">18.2 (390/2,137)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Ischemic heart disease<hr/></td><td align="left" valign="bottom">8.5 (181/2,137)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Heart failure<hr/></td><td align="left" valign="bottom">5.7 (122/2,137)<hr/></td></tr><tr><td align="left" valign="bottom">&#x02003;&#x02009;Cerebrovascular accident<hr/></td><td align="left" valign="bottom">5.6 (120/2,137)<hr/></td></tr><tr><td align="left">&#x02003;&#x02009;Peripheral arteriopathy</td><td align="left">2.8 (60/2,137)</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>CCP: Cyclic citrullinated peptide; SD: Standard deviation. <sup>b</sup>At least two determinations were required for analysis of this result. <sup>c</sup>Extraarticular manifestations of disease (if RA patients had at least one of the following manifestations: nodular disease: Felty&#x02019;s syndrome, pulmonary fibrosis, rheumatoid vasculitis, secondary Sj&#x000f6;gren&#x02019;s syndrome) [<xref ref-type="bibr" rid="B4">4</xref>].</p></table-wrap-foot></table-wrap></sec><sec><title>Genotyping</title><p>Patient DNA was obtained from peripheral blood using standard methods. The <italic>IRF5</italic> rs2004640, rs2070197 and rs10954213 polymorphisms were genotyped with predesigned TaqMan SNP genotyping assays in a 7900HT Fast Real-Time PCR System according to the conditions recommended by the manufacturer (Applied Biosystems, Foster City, CA, USA). Negative controls and duplicate samples were included to check the accuracy of genotyping.</p></sec><sec><title>Statistical analysis</title><p>The genotype data were checked for deviation from Hardy-Weinberg equilibrium (HWE) using a previously described method [<xref ref-type="bibr" rid="B18">18</xref>]. The relationship of genotypes, alleles and haplotypes to CV events that occurred in the follow-up was tested using Cox regression adjusted for sex, age at RA diagnosis and traditional CV disease risk factors. For that purpose, we used the most frequent genotype, allele and haplotype as reference variables. The end of follow-up was the first date of occurrence of the following: end of the study period, date of death or date of CV event. Follow-up time was estimated as the difference between the RA diagnosis date and the end of follow-up. Patients without CV events during the follow-up time and those who died by any non&#x02013;CV-event&#x02013;related cause were censored. The results are expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). In order to have a reference population, 10,000 replications were generated by assigning CV events in randomized fashion to the actual studied population. The proportion of the risk for CV disease due to age at disease diagnosis, smoking history, hypertension and genetic variants at the <italic>IRF5</italic> locus among the RA patients was estimated as the Nelson-Aalen cumulative HR. Comparative values between the different genetic models of inheritance for <italic>IRF5</italic> polymorphisms were estimated using the Akaike Information Criterion (AIC). Statistical significance was defined as <italic>P</italic>&#x02009;&#x02264;&#x02009;0.05, and all analyses were performed using Stata SE/12 statistical software (Stata Corp, College Station, TX, USA).</p></sec></sec><sec sec-type="results"><title>Results</title><p>The <italic>IRF5</italic> rs2004640, rs2070197 and rs10954213 polymorphism genotype distributions were in Hardy-Weinberg equilibrium. The genotyping success rate was greater than 98% in all cases. Genotype and allele frequencies of the <italic>IRF5</italic> rs2004640, rs2070197 and rs10954213 polymorphisms were in agreement with the data in the HapMap database [<xref ref-type="bibr" rid="B19">19</xref>].</p><p>Table&#x000a0;<xref ref-type="table" rid="T2">2</xref> describes those factors that were associated with the risk of CV disease in our cohort of RA patients. As expected, sex and most of the traditional CV disease risk factors (hypertension, dyslipidemia and smoking habit) were associated with increased risk of CV events (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.05 in all cases) (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>). Interestingly, when we analyzed the <italic>IRF5</italic> rs2004640, rs2070197 and rs10954213 polymorphisms separately, we observed a protective effect of the <italic>IRF5</italic> rs2004640 GG genotype against the risk of CV events after adjusting the results for sex, age at RA diagnosis and traditional CV disease risk factors (hypertension, diabetes mellitus, dyslipidemia, obesity and smoking habit) (HR&#x02009;=&#x02009;0.6, 95% CI&#x02009;=&#x02009;0.38 to 0.92, <italic>P</italic>&#x02009;=&#x02009;0.02) (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>). Additionally, the risk of CV disease was decreased in the group of RA patients who carried the <italic>IRF5</italic> rs10954213 GG genotype after we adjusted the results for potential confounders (HR&#x02009;=&#x02009;0.58, 95% CI&#x02009;=&#x02009;0.36 to 0.95, <italic>P</italic>&#x02009;=&#x02009;0.03) (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>). These results were also significant after we estimated by simulation (<italic>P</italic>&#x02009;=&#x02009;0.034 and <italic>P</italic>&#x02009;=&#x02009;0.049 for the <italic>IRF5</italic> rs2004640 GG and rs10954213 GG genotypes, respectively) (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>). However, we found no statistically significant differences when we assessed the <italic>IRF5</italic> rs2070197 polymorphism according to the presence or absence of CV events (Table&#x000a0;<xref ref-type="table" rid="T2">2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p><bold>Factors associated with cardiovascular events in a series of 2,137 rheumatoid patients</bold><sup>
<bold>a</bold>
</sup></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead valign="top"><tr><th align="left"><bold>Variables</bold></th><th align="left">&#x000a0;</th><th align="left"><bold>HR (95% CI)</bold></th><th align="left"><bold>
<italic>P</italic>
</bold><bold>-values</bold></th><th align="left"><bold>
<italic>P</italic>
</bold><bold>-values</bold><sup>
<bold>b</bold>
</sup></th></tr></thead><tbody valign="top"><tr><td align="left" valign="bottom">Males (reference: females)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">1.42 (1.07 to 1.87)<hr/></td><td align="left" valign="bottom">0.015<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Age at RA diagnosis (by each year)<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">1.07 (1.06 to 1.09)<hr/></td><td align="left" valign="bottom">&#x0003c;0.001<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Hypertension<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">1.40 (1.029 to 1.92)<hr/></td><td align="left" valign="bottom">0.032<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Diabetes mellitus<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">1.18 (0.83 to 1.68)<hr/></td><td align="left" valign="bottom">0.344<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Obesity<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">0.93 (0.67 to 1.31)<hr/></td><td align="left" valign="bottom">0.702<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Dyslipidemia<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">1.42 (1.05 to 1.93)<hr/></td><td align="left" valign="bottom">0.022<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">Smoking<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">1.58 (1.26 to 1.99)<hr/></td><td align="left" valign="bottom">&#x0003c;0.001<hr/></td><td align="left" valign="bottom">&#x000a0;<hr/></td></tr><tr><td align="left" valign="bottom">rs2004640<sup>c</sup><hr/></td><td align="left" valign="bottom">TT<hr/></td><td align="left" valign="bottom">1 (reference)<hr/></td><td align="left" valign="bottom">&#x02013;<hr/></td><td align="left" valign="bottom">&#x02013;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">TG<hr/></td><td align="left" valign="bottom">1.07 (0.79 to 1.45)<hr/></td><td align="left" valign="bottom">0.664<hr/></td><td align="left" valign="bottom">0.670<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">GG<hr/></td><td align="left" valign="bottom">0.59 (0.38 to 0.92)<hr/></td><td align="left" valign="bottom">0.020<hr/></td><td align="left" valign="bottom">0.034<hr/></td></tr><tr><td align="left" valign="bottom">rs2070197<sup>c</sup><hr/></td><td align="left" valign="bottom">TT<hr/></td><td align="left" valign="bottom">1 (reference)<hr/></td><td align="left" valign="bottom">&#x02013;<hr/></td><td align="left" valign="bottom">&#x02013;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">TC<hr/></td><td align="left" valign="bottom">1.16 (0.69 to 1.95)<hr/></td><td align="left" valign="bottom">0.58<hr/></td><td align="left" valign="bottom">&#x02013;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">CC<hr/></td><td align="left" valign="bottom">1.32 (0.32 to 5.52)<hr/></td><td align="left" valign="bottom">0.39<hr/></td><td align="left" valign="bottom">&#x02013;<hr/></td></tr><tr><td align="left" valign="bottom">rs10954213<sup>c</sup><hr/></td><td align="left" valign="bottom">AA<hr/></td><td align="left" valign="bottom">1 (reference)<hr/></td><td align="left" valign="bottom">&#x02013;<hr/></td><td align="left" valign="bottom">&#x02013;<hr/></td></tr><tr><td align="left" valign="bottom">&#x000a0;<hr/></td><td align="left" valign="bottom">AG<hr/></td><td align="left" valign="bottom">0.95 (0.71 to 1.26)<hr/></td><td align="left" valign="bottom">0.73<hr/></td><td align="left" valign="bottom">0.738<hr/></td></tr><tr><td align="left">&#x000a0;</td><td align="left">GG</td><td align="left">0.58 (0.36 to 0.95)</td><td align="left">0.03</td><td align="left">0.049</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>CI: Confidence interval; HR: Hazard ratio; RA: Rheumatoid arthritis. <sup>b</sup><italic>P</italic>-values estimated on the basis of 10,000 replications. <sup>c</sup>Adjusted for sex, age at time of rheumatoid arthritis diagnosis and traditional cardiovascular disease risk factors (hypertension, diabetes mellitus, dy<italic>s</italic>lipidemia<italic>,</italic> obesity, smoking habit).</p></table-wrap-foot></table-wrap><p>In a further step, we combined the three polymorphisms to create haplotypes (Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>). As shown in Table&#x000a0;<xref ref-type="table" rid="T3">3</xref>, we detected a protective effect of the GTG haplotype after adjusting the results for sex, age at RA diagnosis and traditional CV disease risk factors (HR&#x02009;=&#x02009;0.72, 95% CI&#x02009;=&#x02009;0.56 to 0.93, <italic>P</italic>&#x02009;=&#x02009;0.012).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p><bold>Results of haplotype analysis in rheumatoid arthritis patients with vs. without cardiovascular disease</bold><sup>
<bold>a</bold>
</sup></p></caption><table frame="hsides" rules="groups" border="1"><colgroup><col align="center"/><col align="center"/><col align="center"/><col align="center"/><col align="center"/></colgroup><thead valign="top"><tr><th colspan="3" align="center" valign="bottom"><bold>Haplotypes</bold><hr/></th><th align="center" valign="bottom"><bold>HR (95% CI)</bold><sup>
<bold>b</bold>
</sup><hr/></th><th align="center" valign="bottom"><bold>P-value</bold><sup>
<bold>b</bold>
</sup><hr/></th></tr><tr><th align="center"><bold>rs2004640</bold></th><th align="center"><bold>rs2070197</bold></th><th align="center"><bold>rs10954213</bold></th><th align="center">&#x000a0;</th><th align="center">&#x000a0;</th></tr></thead><tbody valign="top"><tr><td align="center" valign="bottom">T<hr/></td><td align="center" valign="bottom">T<hr/></td><td align="center" valign="bottom">A<hr/></td><td align="center" valign="bottom">1 (reference)<hr/></td><td align="center" valign="bottom">&#x02013;<hr/></td></tr><tr><td align="center" valign="bottom">G<hr/></td><td align="center" valign="bottom">T<hr/></td><td align="center" valign="bottom">G<hr/></td><td align="center" valign="bottom">0.72 (0.56 to 0.93)<hr/></td><td align="center" valign="bottom">0.012<hr/></td></tr><tr><td align="center" valign="bottom">G<hr/></td><td align="center" valign="bottom">T<hr/></td><td align="center" valign="bottom">A<hr/></td><td align="center" valign="bottom">0.85 (0.61 to 1.18)<hr/></td><td align="center" valign="bottom">0.34<hr/></td></tr><tr><td align="center">T</td><td align="center">C</td><td align="center">A</td><td align="center">1.14 (0.75 to 1.74)</td><td align="center">0.52</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>CI: confidence interval; HR: hazard ratios. <sup>b</sup>Adjusted for sex, age at time of rheumatoid arthritis diagnosis and traditional cardiovascular disease risk factors (hypertension, diabetes mellitus, dyslipidemia<italic>,</italic> obesity and smoking habit).</p></table-wrap-foot></table-wrap><p>Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Table S1 describes the proportion of the CV disease risk disease for RA patients due to age at disease diagnosis, smoking history, hypertension and the genetic variants at the <italic>IRF5</italic> locus. Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>: Table S2 displays the genetic model of inheritance of our analysis. Interestingly, as shown in Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Table S1, the presence of GG genotypes in the <italic>IRF5</italic> rs2004640 and rs1095213 polymorphisms decreased CV disease risk in 0.7% and 1% of patients, respectively (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Table S1). In addition, smoking, age at disease diagnosis and presence of hypertension increased the risk of CV disease (Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>: Table S1). Further, as shown in Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>: Table S2, the AIC estimation for the recessive model showed the lower level in the <italic>IRF5</italic> rs2004640 and rs1095213 polymorphisms, which made it the preferable model for our study (Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>: Table S2).</p></sec><sec sec-type="discussion"><title>Discussion</title><p>CV disease is the most common cause of premature mortality in patients with RA [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. The augmented CV disease mortality observed in this pathology is the result of a compound effect mediated by traditional CV disease risk factors and chronic inflammation [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>]. Because genes have also been associated with an increased risk of CV disease in RA, research in the past several years has been focused on the search for genetic markers that may improve the identification of RA patients at risk of experiencing CV events [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Outside the HLA region, IFN pathway genes, which encode cytokines with critical modulatory effects on innate and adaptive immunity, have been shown to represent a key component of the genetic network leading to autoimmune processes. In this context, several polymorphisms in the <italic>IRF5</italic> gene (a regulator of type I IFN induction) [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>] are associated with an increased risk of immune-mediated diseases [<xref ref-type="bibr" rid="B13">13</xref>,<xref ref-type="bibr" rid="B14">14</xref>]. Because of that, in this study we analyzed three genetic variants (<italic>IRF5</italic> rs2004640, rs2070197 and rs10954213) as representatives of three different <italic>IRF5</italic> haplotype blocks [<xref ref-type="bibr" rid="B14">14</xref>]. To the best of our knowledge, our study constitutes the largest series of RA patients assessed for the potential influence of <italic>IRF5</italic> polymorphisms in the risk of CV disease. Interestingly, when we studied each of the polymorphisms separately, our results revealed a protective effect of the <italic>IRF5</italic> rs2004640 GG and <italic>IRF5</italic> rs10954213 GG genotype variants against the risk of CV events in RA. Moreover, when we analyzed all the genetic variants together to create haplotypes, our results revealed a protective effect of the GTG haplotype (the one that carries both G alleles of <italic>IRF5</italic> rs2004640 and rs10954213 polymorphisms) against the risk of CV disease. Because the protective effect of the mutant allele of the <italic>IRF5</italic> rs2004640 and rs1095213 polymorphisms is seen only in homozygosis, we can conclude that our study is adjusted to a recessive model of inheritance. Additionally, the results derived from our study are in accordance with those obtained in other pathologies [<xref ref-type="bibr" rid="B20">20</xref>,<xref ref-type="bibr" rid="B21">21</xref>]. In this context, the results of a recent study of individuals diagnosed with RA revealed an association between the <italic>IRF5</italic> rs2004640 polymorphism and subclinical atherosclerosis [<xref ref-type="bibr" rid="B22">22</xref>].</p><p>The results obtained in this study provide additional evidence on the potential role that genetic factors may play in the development of CV disease in RA. The search for genetic markers associated with CV disease in RA may be important to establishing a better characterization of RA patients at risk of CV disease. Improved understanding of these underlying genetic may be useful to establish future therapeutic targets to decrease the risk of CV disease in RA patients.</p></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Our results reveal that <italic>IRF5</italic> gene variants are associated with CV disease in RA patients.</p></sec><sec><title>Abbreviations</title><p>ACR: American College of Rheumatology; Anti-CCP: Anti&#x02013;cyclic citrullinated protein/peptide antibody; CI: Confidence interval; CV: Cardiovascular; HLA: Human leukocyte antigen; HR: Hazard ratio; IFN: Interferon; IL: Interleukin; IRF: Interferon regulatory factor; RA: Rheumatoid arthritis; SD: Standard deviation; SLE: Systemic lupus erythematosus; SNP: Single-nucleotide polymorphism; TNF: Tumor necrosis factor.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors&#x02019; contributions</title><p>MGB, RLM and FG carried out genotyping, participated in the study design and data analysis and helped to draft the manuscript. SC and BFG were involved in the acquisition and interpretation of data and in revising the manuscript critically for important intellectual content. JL carried out data analysis and interpretation. AC and CGJ performed the carotid ultrasound examination and were involved in the acquisition and interpretation of data as well as study coordination, and they helped to draft the manuscript. BU, JAMF, TP, CGV, LRR, AB, DPS FJLL, PC and RB participated in the acquisition and interpretation of data and helped to draft the manuscript. JM and MAGG made substantial contributions to the study&#x02019;s conception and design, data acquisition and study coordination, and they helped to draft the manuscript. All authors read and approved the final manuscript.</p></sec><sec><title>Authors&#x02019; information</title><p>JM and MAGG share senior authorship of this article.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1: Table S1</title><p>Proportion of the CV risk for RA patients due to age, smoking history, hypertension and the genetic variants at the <italic>IRF5</italic> locus at 5&#x000a0;years.</p></caption><media xlink:href="ar4608-S1.doc"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2: Table S2</title><p>Comparison between different genetic models of inheritance for <italic>IRF5</italic> polymorphisms.</p></caption><media xlink:href="ar4608-S2.doc"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><sec><title>Acknowledgements</title><p>We wish to thank all the patients with RA who participated and made this study possible. We want to especially thank Sof&#x000ed;a Vargas, Rodrigo Ochoa, M Luisa L&#x000f3;pez, M Jes&#x000fa;s Iba&#x000f1;ez and Sara Olavarria for their technical assistance. This study was supported by European Union FEDER funds (European Fund for Regional Development) and the Health Research Fund (Fondo de Investigaci&#x000f3;n Sanitaria grants PI06/0024, PS09/00748 and PI12/00060) from Instituto de Salud Carlos III (ISCIII, Health Ministry, Spain). It was also partially supported by Cooperative Health Research Thematic Network (RETICS) Program RD12/0009 (RIER) from Instituto de Salud Carlos III (ISCIII, Health Ministry, Spain) and by grants from the European Innovative Medicines Initiative Be the Cure (IMI BTCure) program. RLM is a recipient of a Sara Borrell postdoctoral fellowship from the Instituto Carlos III de Salud at the Spanish Ministry of Health (CD12/00425). FG and BU are supported by funds from the RETICS Program (RIER) (RD12/0009/0013).</p></sec><ref-list><ref id="B1"><mixed-citation publication-type="journal"><name><surname>Avina-Zubieta</surname><given-names>JA</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Sadatsafavi</surname><given-names>M</given-names></name><name><surname>Lehman</surname><given-names>AJ</given-names></name><name><surname>Lacaille</surname><given-names>D</given-names></name><article-title>Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies</article-title><source>Ann Rheum Dis</source><year>2012</year><volume>71</volume><fpage>1524</fpage><lpage>1529</lpage><pub-id pub-id-type="pmid">22425941</pub-id></mixed-citation></ref><ref id="B2"><mixed-citation publication-type="journal"><name><surname>Solomon</surname><given-names>DH</given-names></name><name><surname>Goodson</surname><given-names>NJ</given-names></name><name><surname>Katz</surname><given-names>JN</given-names></name><name><surname>Weinblatt</surname><given-names>ME</given-names></name><name><surname>Avorn</surname><given-names>J</given-names></name><name><surname>Setoguchi</surname><given-names>S</given-names></name><name><surname>Canning</surname><given-names>C</given-names></name><name><surname>Schneeweiss</surname><given-names>S</given-names></name><article-title>Patterns of cardiovascular risk in rheumatoid arthritis</article-title><source>Ann Rheum Dis</source><year>2006</year><volume>65</volume><fpage>1608</fpage><lpage>1612</lpage><pub-id pub-id-type="pmid">16793844</pub-id></mixed-citation></ref><ref id="B3"><mixed-citation publication-type="journal"><name><surname>Dessein</surname><given-names>PH</given-names></name><name><surname>Norton</surname><given-names>GR</given-names></name><name><surname>Woodiwiss</surname><given-names>AJ</given-names></name><name><surname>Joffe</surname><given-names>BI</given-names></name><name><surname>Wolfe</surname><given-names>F</given-names></name><article-title>Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis</article-title><source>J Rheumatol</source><year>2007</year><volume>34</volume><fpage>943</fpage><lpage>951</lpage><pub-id pub-id-type="pmid">17444592</pub-id></mixed-citation></ref><ref id="B4"><mixed-citation publication-type="journal"><name><surname>Gonzalez-Gay</surname><given-names>MA</given-names></name><name><surname>Gonzalez-Juanatey</surname><given-names>C</given-names></name><name><surname>Lopez-Diaz</surname><given-names>MJ</given-names></name><name><surname>Pineiro</surname><given-names>A</given-names></name><name><surname>Garcia-Porrua</surname><given-names>C</given-names></name><name><surname>Miranda-Filloy</surname><given-names>JA</given-names></name><name><surname>Ollier</surname><given-names>WE</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><article-title><italic>HLA-DRB1</italic> and persistent chronic inflammation contribute to cardiovascular events and cardiovascular mortality in patients with rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>2007</year><volume>57</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="pmid">17266100</pub-id></mixed-citation></ref><ref id="B5"><mixed-citation publication-type="journal"><name><surname>Garc&#x000ed;a-Berm&#x000fa;dez</surname><given-names>M</given-names></name><name><surname>Gonz&#x000e1;lez-Juanatey</surname><given-names>C</given-names></name><name><surname>L&#x000f3;pez-Mej&#x000ed;as</surname><given-names>R</given-names></name><name><surname>Teruel</surname><given-names>M</given-names></name><name><surname>Corrales</surname><given-names>A</given-names></name><name><surname>Miranda-Filloy</surname><given-names>JA</given-names></name><name><surname>Casta&#x000f1;eda</surname><given-names>S</given-names></name><name><surname>Balsa</surname><given-names>A</given-names></name><name><surname>Fern&#x000e1;ndez-Gutierrez</surname><given-names>B</given-names></name><name><surname>Gonz&#x000e1;lez-&#x000c1;lvaro</surname><given-names>I</given-names></name><name><surname>G&#x000f3;mez-Vaquero</surname><given-names>C</given-names></name><name><surname>Blanco</surname><given-names>R</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J</given-names></name><name><surname>Gonz&#x000e1;lez-Gay</surname><given-names>MA</given-names></name><article-title>Study of association of <italic>CD40-CD154</italic> gene polymorphisms with disease susceptibility and cardiovascular risk in Spanish rheumatoid arthritis patients</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e49214</fpage><pub-id pub-id-type="pmid">23166616</pub-id></mixed-citation></ref><ref id="B6"><mixed-citation publication-type="journal"><name><surname>Garc&#x000ed;a-Berm&#x000fa;dez</surname><given-names>M</given-names></name><name><surname>L&#x000f3;pez-Mej&#x000ed;as</surname><given-names>R</given-names></name><name><surname>Genre</surname><given-names>F</given-names></name><name><surname>Casta&#x000f1;eda</surname><given-names>S</given-names></name><name><surname>Gonz&#x000e1;lez-Juanatey</surname><given-names>C</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><name><surname>Corrales</surname><given-names>A</given-names></name><name><surname>Miranda-Filloy</surname><given-names>JA</given-names></name><name><surname>Rueda-Gotor</surname><given-names>J</given-names></name><name><surname>G&#x000f3;mez-Vaquero</surname><given-names>C</given-names></name><name><surname>Rodr&#x000ed;guez-Rodr&#x000ed;guez</surname><given-names>L</given-names></name><name><surname>Fern&#x000e1;ndez-Guti&#x000e9;rrez</surname><given-names>B</given-names></name><name><surname>Pascual-Salcedo</surname><given-names>D</given-names></name><name><surname>Balsa</surname><given-names>A</given-names></name><name><surname>L&#x000f3;pez-Longo</surname><given-names>FJ</given-names></name><name><surname>Carreira</surname><given-names>P</given-names></name><name><surname>Blanco</surname><given-names>R</given-names></name><name><surname>Gonz&#x000e1;lez-&#x000c1;lvaro</surname><given-names>I</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J</given-names></name><name><surname>Gonz&#x000e1;lez-Gay</surname><given-names>MA</given-names></name><article-title><italic>SMAD3</italic> rs17228212 gene polymorphism is associated with reduced risk to cerebrovascular accidents and subclinical atherosclerosis in anti-CCP negative Spanish rheumatoid arthritis patients</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e77695</fpage><pub-id pub-id-type="pmid">24204921</pub-id></mixed-citation></ref><ref id="B7"><mixed-citation publication-type="journal"><name><surname>L&#x000f3;pez-Mej&#x000ed;as</surname><given-names>R</given-names></name><name><surname>Garc&#x000ed;a-Berm&#x000fa;dez</surname><given-names>M</given-names></name><name><surname>Gonz&#x000e1;lez-Juanatey</surname><given-names>C</given-names></name><name><surname>Casta&#x000f1;eda</surname><given-names>S</given-names></name><name><surname>Miranda-Filloy</surname><given-names>JA</given-names></name><name><surname>G&#x000f3;mez-Vaquero</surname><given-names>C</given-names></name><name><surname>Fern&#x000e1;ndez-Guti&#x000e9;rrez</surname><given-names>B</given-names></name><name><surname>Balsa</surname><given-names>A</given-names></name><name><surname>Pascual-Salcedo</surname><given-names>D</given-names></name><name><surname>Blanco</surname><given-names>R</given-names></name><name><surname>Gonz&#x000e1;lez-&#x000c1;lvaro</surname><given-names>I</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J</given-names></name><name><surname>Gonz&#x000e1;lez-Gay</surname><given-names>MA</given-names></name><article-title><italic>NFKB1</italic>-94ATTG ins/del polymorphism (rs28362491) is associated with cardiovascular disease in patients with rheumatoid arthritis</article-title><source>Atherosclerosis</source><year>2012</year><volume>224</volume><fpage>426</fpage><lpage>429</lpage><pub-id pub-id-type="pmid">22742859</pub-id></mixed-citation></ref><ref id="B8"><mixed-citation publication-type="journal"><name><surname>L&#x000f3;pez-Mej&#x000ed;as</surname><given-names>R</given-names></name><name><surname>Genre</surname><given-names>F</given-names></name><name><surname>Garc&#x000ed;a-Berm&#x000fa;dez</surname><given-names>M</given-names></name><name><surname>Corrales</surname><given-names>A</given-names></name><name><surname>Gonz&#x000e1;lez-Juanatey</surname><given-names>C</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><name><surname>Miranda-Filloy</surname><given-names>JA</given-names></name><name><surname>Rueda-Gotor</surname><given-names>J</given-names></name><name><surname>Blanco</surname><given-names>R</given-names></name><name><surname>Casta&#x000f1;eda</surname><given-names>S</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J</given-names></name><name><surname>Gonz&#x000e1;lez-Gay</surname><given-names>MA</given-names></name><article-title>The <italic>ZC3HC1</italic> rs11556924 polymorphism is associated with increased carotid intima-media thickness in patients with rheumatoid arthritis</article-title><source>Arthritis Res Ther</source><year>2013</year><volume>15</volume><fpage>R152</fpage><pub-id pub-id-type="pmid">24286297</pub-id></mixed-citation></ref><ref id="B9"><mixed-citation publication-type="journal"><name><surname>Higgs</surname><given-names>BW</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>White</surname><given-names>B</given-names></name><name><surname>Zhu</surname><given-names>W</given-names></name><name><surname>White</surname><given-names>WI</given-names></name><name><surname>Morehouse</surname><given-names>C</given-names></name><name><surname>Brohawn</surname><given-names>P</given-names></name><name><surname>Kiener</surname><given-names>PA</given-names></name><name><surname>Richman</surname><given-names>L</given-names></name><name><surname>Fiorentino</surname><given-names>D</given-names></name><name><surname>Greenberg</surname><given-names>SA</given-names></name><name><surname>Jallal</surname><given-names>B</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><article-title>Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway</article-title><source>Ann Rheum Dis</source><year>2011</year><volume>70</volume><fpage>2029</fpage><lpage>2036</lpage><pub-id pub-id-type="pmid">21803750</pub-id></mixed-citation></ref><ref id="B10"><mixed-citation publication-type="journal"><name><surname>Schoenemeyer</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>BJ</given-names></name><name><surname>Mancl</surname><given-names>ME</given-names></name><name><surname>Latz</surname><given-names>E</given-names></name><name><surname>Goutagny</surname><given-names>N</given-names></name><name><surname>Pitha</surname><given-names>PM</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Golenbock</surname><given-names>DT</given-names></name><article-title>The interferon regulatory factor, IRF5, is a central mediator of Toll-like receptor 7 signaling</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>17005</fpage><lpage>17012</lpage><pub-id pub-id-type="pmid">15695821</pub-id></mixed-citation></ref><ref id="B11"><mixed-citation publication-type="journal"><name><surname>Barnes</surname><given-names>BJ</given-names></name><name><surname>Moore</surname><given-names>PA</given-names></name><name><surname>Pitha</surname><given-names>PM</given-names></name><article-title>Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon &#x003b1; genes</article-title><source>J Biol Chem</source><year>2001</year><volume>276</volume><fpage>23382</fpage><lpage>23390</lpage><pub-id pub-id-type="pmid">11303025</pub-id></mixed-citation></ref><ref id="B12"><mixed-citation publication-type="journal"><name><surname>Krausgruber</surname><given-names>T</given-names></name><name><surname>Blazek</surname><given-names>K</given-names></name><name><surname>Smallie</surname><given-names>T</given-names></name><name><surname>Alzabin</surname><given-names>S</given-names></name><name><surname>Lockstone</surname><given-names>H</given-names></name><name><surname>Sahgal</surname><given-names>N</given-names></name><name><surname>Hussell</surname><given-names>T</given-names></name><name><surname>Feldmann</surname><given-names>M</given-names></name><name><surname>Udalova</surname><given-names>IA</given-names></name><article-title>IRF5 promotes inflammatory macrophage polarization and T<sub>H</sub>1-T<sub>H</sub>17 responses</article-title><source>Nat Immunol</source><year>2011</year><volume>12</volume><fpage>231</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">21240265</pub-id></mixed-citation></ref><ref id="B13"><mixed-citation publication-type="journal"><name><surname>Eyre</surname><given-names>S</given-names></name><name><surname>Bowes</surname><given-names>J</given-names></name><name><surname>Diogo</surname><given-names>D</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Barton</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>P</given-names></name><name><surname>Zhernakova</surname><given-names>A</given-names></name><name><surname>Stahl</surname><given-names>E</given-names></name><name><surname>Viatte</surname><given-names>S</given-names></name><name><surname>McAllister</surname><given-names>K</given-names></name><name><surname>Amos</surname><given-names>CI</given-names></name><name><surname>Padyukov</surname><given-names>L</given-names></name><name><surname>Toes</surname><given-names>RE</given-names></name><name><surname>Huizinga</surname><given-names>TW</given-names></name><name><surname>Wijmenga</surname><given-names>C</given-names></name><name><surname>Trynka</surname><given-names>G</given-names></name><name><surname>Franke</surname><given-names>L</given-names></name><name><surname>Westra</surname><given-names>HJ</given-names></name><name><surname>Alfredsson</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name><name><surname>Sandor</surname><given-names>C</given-names></name><name><surname>de Bakker</surname><given-names>PI</given-names></name><name><surname>Davila</surname><given-names>S</given-names></name><name><surname>Khor</surname><given-names>CC</given-names></name><name><surname>Heng</surname><given-names>KK</given-names></name><name><surname>Andrews</surname><given-names>R</given-names></name><name><surname>Edkins</surname><given-names>S</given-names></name><name><surname>Hunt</surname><given-names>SE</given-names></name><name><surname>Langford</surname><given-names>C</given-names></name><name><surname>Symmons</surname><given-names>D</given-names></name><etal/><article-title>High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis</article-title><source>Nat Genet</source><year>2012</year><volume>44</volume><fpage>1336</fpage><lpage>1340</lpage><pub-id pub-id-type="pmid">23143596</pub-id></mixed-citation></ref><ref id="B14"><mixed-citation publication-type="journal"><name><surname>Graham</surname><given-names>RR</given-names></name><name><surname>Kozyrev</surname><given-names>SV</given-names></name><name><surname>Baechler</surname><given-names>EC</given-names></name><name><surname>Reddy</surname><given-names>MV</given-names></name><name><surname>Plenge</surname><given-names>RM</given-names></name><name><surname>Bauer</surname><given-names>JW</given-names></name><name><surname>Ortmann</surname><given-names>WA</given-names></name><name><surname>Koeuth</surname><given-names>T</given-names></name><name><surname>Gonz&#x000e1;lez Escribano</surname><given-names>MF</given-names></name><name><surname>Pons-Estel</surname><given-names>B</given-names></name><name><surname>Petri</surname><given-names>M</given-names></name><name><surname>Daly</surname><given-names>M</given-names></name><name><surname>Gregersen</surname><given-names>PK</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Behrens</surname><given-names>TW</given-names></name><name><surname>Alarc&#x000f3;n-Riquelme</surname><given-names>ME</given-names></name><collab>Argentine and Spanish Collaborative Groups</collab><article-title>A common haplotype of interferon regulatory factor 5 (<italic>IRF5</italic>) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus</article-title><source>Nat Genet</source><year>2006</year><volume>38</volume><fpage>550</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">16642019</pub-id></mixed-citation></ref><ref id="B15"><mixed-citation publication-type="journal"><name><surname>Arnett</surname><given-names>FC</given-names></name><name><surname>Edworthy</surname><given-names>SM</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><name><surname>McShane</surname><given-names>DJ</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><name><surname>Cooper</surname><given-names>NS</given-names></name><name><surname>Healey</surname><given-names>LA</given-names></name><name><surname>Kaplan</surname><given-names>SR</given-names></name><name><surname>Liang</surname><given-names>MH</given-names></name><name><surname>Luthra</surname><given-names>HS</given-names></name><name><surname>Medsger</surname><given-names>TA</given-names><suffix>Jr</suffix></name><name><surname>Mitchell</surname><given-names>DM</given-names></name><name><surname>Neustadt</surname><given-names>DH</given-names></name><name><surname>Pinals</surname><given-names>RS</given-names></name><name><surname>Schaller</surname><given-names>JG</given-names></name><name><surname>Sharp</surname><given-names>JT</given-names></name><name><surname>Wilder</surname><given-names>RL</given-names></name><name><surname>Hunder</surname><given-names>GG</given-names></name><article-title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</article-title><source>Arthritis Rheum</source><year>1988</year><volume>31</volume><fpage>315</fpage><lpage>324</lpage><pub-id pub-id-type="pmid">3358796</pub-id></mixed-citation></ref><ref id="B16"><mixed-citation publication-type="journal"><name><surname>Aletaha</surname><given-names>D</given-names></name><name><surname>Neogi</surname><given-names>T</given-names></name><name><surname>Silman</surname><given-names>AJ</given-names></name><name><surname>Funovits</surname><given-names>J</given-names></name><name><surname>Felson</surname><given-names>DT</given-names></name><name><surname>Bingham</surname><given-names>CO</given-names><suffix>3rd</suffix></name><name><surname>Birnbaum</surname><given-names>NS</given-names></name><name><surname>Burmester</surname><given-names>GR</given-names></name><name><surname>Bykerk</surname><given-names>VP</given-names></name><name><surname>Cohen</surname><given-names>MD</given-names></name><name><surname>Combe</surname><given-names>B</given-names></name><name><surname>Costenbader</surname><given-names>KH</given-names></name><name><surname>Dougados</surname><given-names>M</given-names></name><name><surname>Emery</surname><given-names>P</given-names></name><name><surname>Ferraccioli</surname><given-names>G</given-names></name><name><surname>Hazes</surname><given-names>JM</given-names></name><name><surname>Hobbs</surname><given-names>K</given-names></name><name><surname>Huizinga</surname><given-names>TW</given-names></name><name><surname>Kavanaugh</surname><given-names>A</given-names></name><name><surname>Kay</surname><given-names>J</given-names></name><name><surname>Kvien</surname><given-names>TK</given-names></name><name><surname>Laing</surname><given-names>T</given-names></name><name><surname>Mease</surname><given-names>P</given-names></name><name><surname>M&#x000e9;nard</surname><given-names>HA</given-names></name><name><surname>Moreland</surname><given-names>LW</given-names></name><name><surname>Naden</surname><given-names>RL</given-names></name><name><surname>Pincus</surname><given-names>T</given-names></name><name><surname>Smolen</surname><given-names>JS</given-names></name><name><surname>Stanislawska-Biernat</surname><given-names>E</given-names></name><name><surname>Symmons</surname><given-names>D</given-names></name><etal/><article-title>2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative</article-title><source>Arthritis Rheum</source><year>2010</year><volume>62</volume><fpage>2569</fpage><lpage>2581</lpage><pub-id pub-id-type="pmid">20872595</pub-id></mixed-citation></ref><ref id="B17"><mixed-citation publication-type="journal"><name><surname>Gonzalez-Juanatey</surname><given-names>C</given-names></name><name><surname>Llorca</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>J</given-names></name><name><surname>Gonzalez-Gay</surname><given-names>MA</given-names></name><article-title>Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis</article-title><source>Semin Arthritis Rheum</source><year>2009</year><volume>38</volume><fpage>366</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">18336869</pub-id></mixed-citation></ref><ref id="B18"><mixed-citation publication-type="other"><collab>Institut f&#x000fc;r Humangenetik</collab><article-title>Case&#x02013;Control Studies: Tests for Deviation from Hardy-Weinberg Equilibrium and Tests for Association</article-title><comment>[<ext-link ext-link-type="uri" xlink:href="http://ihg.gsf.de/cgi-bin/hw/hwa1.pl">http://ihg.gsf.de/cgi-bin/hw/hwa1.pl</ext-link>]</comment></mixed-citation></ref><ref id="B19"><mixed-citation publication-type="other"><article-title>International HapMap Project</article-title><comment>[<ext-link ext-link-type="uri" xlink:href="http://hapmap.ncbi.nlm.nih.gov/">http://hapmap.ncbi.nlm.nih.gov/</ext-link>]</comment></mixed-citation></ref><ref id="B20"><mixed-citation publication-type="journal"><name><surname>Carmona</surname><given-names>FD</given-names></name><name><surname>Martin</surname><given-names>JE</given-names></name><name><surname>Beretta</surname><given-names>L</given-names></name><name><surname>Sime&#x000f3;n</surname><given-names>CP</given-names></name><name><surname>Carreira</surname><given-names>PE</given-names></name><name><surname>Callejas</surname><given-names>JL</given-names></name><name><surname>Fern&#x000e1;ndez-Castro</surname><given-names>M</given-names></name><name><surname>S&#x000e1;ez-Comet</surname><given-names>L</given-names></name><name><surname>Beltr&#x000e1;n</surname><given-names>E</given-names></name><name><surname>Camps</surname><given-names>MT</given-names></name><name><surname>Egurbide</surname><given-names>MV</given-names></name><name><surname>Air&#x000f3;</surname><given-names>P</given-names></name><name><surname>Scorza</surname><given-names>R</given-names></name><name><surname>Lunardi</surname><given-names>C</given-names></name><name><surname>Hunzelmann</surname><given-names>N</given-names></name><name><surname>Riemekasten</surname><given-names>G</given-names></name><name><surname>Witte</surname><given-names>T</given-names></name><name><surname>Kreuter</surname><given-names>A</given-names></name><name><surname>Distler</surname><given-names>JHW</given-names></name><name><surname>Madhok</surname><given-names>R</given-names></name><name><surname>Shiels</surname><given-names>P</given-names></name><name><surname>van Laar</surname><given-names>JM</given-names></name><name><surname>Fonseca</surname><given-names>C</given-names></name><name><surname>Denton</surname><given-names>C</given-names></name><name><surname>Herrick</surname><given-names>A</given-names></name><name><surname>Worthington</surname><given-names>J</given-names></name><name><surname>Schuerwegh</surname><given-names>AJ</given-names></name><name><surname>Vonk</surname><given-names>MC</given-names></name><name><surname>Voskuyl</surname><given-names>AE</given-names></name><collab>the Spanish Scleroderma Group</collab><etal/><article-title>The systemic lupus erythematosus <italic>IRF5</italic> risk haplotype is associated with systemic sclerosis</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e54419</fpage><pub-id pub-id-type="pmid">23372721</pub-id></mixed-citation></ref><ref id="B21"><mixed-citation publication-type="journal"><name><surname>Fan</surname><given-names>JH</given-names></name><name><surname>Gao</surname><given-names>LB</given-names></name><name><surname>Pan</surname><given-names>XM</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Liang</surname><given-names>WB</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><article-title>Association between <italic>IRF-5</italic> polymorphisms and risk of acute coronary syndrome</article-title><source>DNA Cell Biol</source><year>2010</year><volume>29</volume><fpage>19</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">19778284</pub-id></mixed-citation></ref><ref id="B22"><mixed-citation publication-type="journal"><name><surname>Vosslamber</surname><given-names>S</given-names></name><name><surname>van Sijl</surname><given-names>A</given-names></name><name><surname>Bos</surname><given-names>CL</given-names></name><name><surname>Lubbers</surname><given-names>J</given-names></name><name><surname>de Ridder</surname><given-names>S</given-names></name><name><surname>Voskuyl</surname><given-names>AE</given-names></name><name><surname>Nurmohamed</surname><given-names>MT</given-names></name><name><surname>Verweij</surname><given-names>CL</given-names></name><article-title>Interferon regulatory factor 5 (<italic>IRF5</italic>) gene variant rs2004640 is associated with carotid intima media thickness in rheumatoid arthritis patients [abstract A1.77]</article-title><source>Ann Rheum Dis</source><year>2014</year><volume>73</volume><fpage>A34</fpage></mixed-citation></ref></ref-list></back></article>